• Corpus ID: 9640884

Medications and Myasthenia Gravis ( A Reference for Health Care Professionals )

  title={Medications and Myasthenia Gravis ( A Reference for Health Care Professionals )},
  author={Mehyar Mehrizi and Rodrigue F. Fontem and Tiffany R. Gearhart and Robert M. Pascuzzi},
Introduction Patients with myasthenia gravis (MG) or Lambert-Eaton syndrome (LES) may have worsening of symptoms upon exposure to a variety of medications. Underlying disorders of neuromuscular transmission may affect presynaptic release of acetylcholine (LES) or the postsynaptic muscle fiber membrane at the endplate (MG). Similarly, adverse drug effects can occur presynaptically or postsynaptically. In a patient with a reduced safety factor for neuromuscular transmission, exposure to a drug or… 

Management of myasthenia gravis in daily practice for general neurologists and healthcare professionals

The present review aims to improve the understanding of current MG diagnosis, specific immunotherapy and clinical management tips, not only for the general neurologist, but also for other medical staff.

Perianesthetic Implications and Considerations for Myasthenia Gravis

Drug-induced myasthenic syndromes

The author draws attention to the rare occurrence of drug-induced myasthenia with a new class of anticancer drugs, the immune checkpoint inhibitors, which include the drug ipilimumab targeting cytotoxic lymphocyte-associated protein 4 (CTLA-4), and the drugs nivolumab and pembrolizumab targeting programmed cell death-1 (PD-1).

Italian recommendations for the diagnosis and treatment of myasthenia gravis

For patients refractory to conventional immunosuppression, the use of biologic agents is highly promising and the diagnostic procedures and therapeutic approaches hereafter described are largely accessible in Italy.

Iranian Consensus Recommendations for Treatment of Myasthenia Gravis.

A group of Iranian neuromuscular specialists have written these recommendations to treat MG based on national conditions to help healthcare professionals in proper treatment and follow-up of patients with MG.

Dentistry and the myasthenia gravis patient: a review of the current state of the art.

Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis

Pyridostigmine is being prescribed at doses close to the defined daily doses predominantly as monotherapy, and a high proportion of patients were also prescribed a medication that could aggravate their condition, including some that can trigger a myasthenic crisis.

Acute Respiratory Failure Induced by Magnesium Replacement in a 62-Year-Old Woman with Myasthenia Gravis.

The case of a 62-year-old woman with myasthenia gravis and a metastatic thymoma who was admitted to the intensive care unit for management of aMyasthenic crisis is described, and the patient's neuromuscular weakness worsened in association with standard intravenous magnesium replacement.

Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review

The first case of anti-MUSK (+) MG is presented in a woman with metastatic BRAF-mutant melanoma after long-term treatment with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor), and MG was confirmed by both autoantibodies and nerve-conduction tests.



Drug‐Induced Neuromuscular Blockade and Myasthenia Gravis

Drugs most likely to impact myasthenic patients negatively are those used in the treatment of the disease, including overuse of anticholinesterase drugs, high‐dose prednisone, and anesthesia and neuromuscular blockers for thymectomy.

Effect of d-penicillamine on neuromuscular junction in patients with Wilson disease

The effect of d-penicillamine on the neuromuscular junction and the presence of acetylcholine receptor (AChR) antibody in the sera of patients with Wilson disease (WD) are investigated.

Statin-associated exacerbation of myasthenia gravis

A patient with well-documented MG is presented who experienced worsening of his condition after taking different statins on four separate occasions, and it is not clear that this patient had MG.

Myasthenic syndrome during treatment with practolol.

  • L. Wislicki
  • Medicine, Biology
    British medical journal
  • 1976
As in experimental animals the neuromuscular effects of '3-adrenoceptor blockers are readily reversible the risk of a relapse of the myasthenic syndrome seems to be remote, however, the patient may be hypersensitive to D-tubocurarine and related agents and also to drugs with a local anaesthetic action, like quinidine.

Drugs and myasthenia gravis. An update.

  • E. Wittbrodt
  • Medicine, Biology
    Archives of internal medicine
  • 1997
A small subset of drugs have been implicated in the pathogenesis of a variant of the disease, most notably the antirheumatic agent penicillamine, which is associated with clinical worsening of existing myasthenia gravis.

Quinidine-induced exacerbation of myasthenia gravis in patient with Graves' disease.

A patient with Graves' disease and complicating atrial fibrillation for which his family physician had administered quinidine precipitated obvious and frightening symptoms of myasthenia gravis, and evaluation indicated underlying hyperthyroidism.

Development of myasthenia gravis after interferon alpha therapy.

Autoimmune mechanisms, as the release of different cytokines as IFN, by immunocompetent cells, may be involved in the pathogenesis of both MG and chronic active hepatitis, and autoantibody production against postsynaptic membrane structures by IFN-alpha could be the underlying pathophysiology.

Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome

These observations suggest that tandutinib is toxic to the neuromuscular junction, possibly by reversibly binding to a molecule on the postsynaptic acetylcholine receptor complex.

D-penicillamine induced myasthenia gravis: clinical, serological and genetic findings.

DP-related MG is relatively benign, although it sometimes can cause life-threatening muscle weakness requiring aggressive therapy, although the relatively small number of patients included in this study does not permit any firm conclusions regarding the HLA associations of DP- related MG.

Probable exacerbation of myasthenia gravis by ofloxacin

1. Arendt G, Hefter H, Elsing C, Strohmeyer G, Freund HJ (1990) Motor dysfunction in HIV-infected patients without clinically detectable central nervous deficit. J Neurol 237 : 362-368 2. DeGans J,